Skip to content
Clinical Trials for Alzheimer's Disease

Massachusetts

Alzheimer's disease clinical trials in Massachusetts

48 Alzheimer's disease studies are recruiting participants at sites in 17 cities across Massachusetts as of November 16, 2026, according to ClinicalTrials.gov.

Call (888) 927-5895
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Browse Massachusetts by city

Cities with the most studies recruiting right now.

Every Massachusetts city with a recruiting study

Boston (27), Newton (8), Watertown (6), Cambridge (4), Belmont (2), Foxborough (2), Plymouth (2), Springfield (2), Winchester (2), Amherst (1), Braintree (1), Charlestown (1), Methuen (1), North Dartmouth (1), Roslindale (1), South Dartmouth (1), Waltham (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Recently updated studies in Massachusetts

Basic details from each study's public record (the 12 most recently updated of 48). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)

    • Observational
    • Ages 30 to 90
    • All sexes
    Sponsor
    VA Office of Research and Development
    Recruiting in
    Boston
    Registry record
    NCT04124029 · updated
  2. Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

    • Phase 3
    • Ages 50 to 90
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Recruiting in
    Boston · Newton · Watertown
    Registry record
    NCT07177352 · updated
  3. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Newton
    Registry record
    NCT06937229 · updated
  4. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Newton · South Dartmouth · Springfield
    Registry record
    NCT07011732 · updated
  5. A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

    • Phase 2
    • Ages 55 to 85
    • All sexes
    Sponsor
    Sanofi
    Recruiting in
    Newton
    Registry record
    NCT07688213 · updated
  6. A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

    • Phase 3
    • Ages 55 to 80
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Recruiting in
    Boston · Newton · Watertown
    Registry record
    NCT07717411 · updated
  7. A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

    • Phase 2
    • Ages 55 to 85
    • All sexes
    Sponsor
    Eli Lilly and Company
    Recruiting in
    Foxborough · Plymouth
    Registry record
    NCT07589595 · updated
  8. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Recruiting in
    Boston
    Registry record
    NCT06651567 · updated
  9. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

    • Phase 3
    • Ages 55 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Recruiting in
    Newton · Waltham
    Registry record
    NCT07602582 · updated
  10. Triage Survey for Neurology Research Eligibility

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Adams Clinical
    Recruiting in
    Watertown
    Registry record
    NCT06104852 · updated
  11. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Recruiting in
    Belmont · Boston · North Dartmouth · and 1 more U.S. location
    Registry record
    NCT06585787 · updated
  12. A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

    • Phase 3
    • Ages 60 to 85
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Newton
    Registry record
    NCT06976216 · updated

Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in Massachusetts on ClinicalTrials.gov.

Ask about studies in Massachusetts

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Clinical Trials for Alzheimer's Disease does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5895

or send a short form

How should we reach you?

Call